Is TSRX a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

1,185 people get TSRX articles and Market Currents by email alert.

Get email alerts on TSRX »

HEADLINES:

SmithOnStocks Opines On Stocks: May 19th Edition
Smith On Stocks • Sun, May 19 • 2 Comments
Trius Patent Intrigues Investors, And Perhaps Cubist Pharmaceuticals
PropThink • Thu, May 16 • 3 Comments
Trius Therapeutics: New, Positive Dimension For Investment Outlook
Smith On Stocks • Mon, May 13 • 5 Comments
Trius Announces Notice of Allowance of U.S. Patent Application Related to Tedizolid Phosphate Combination With Daptomycin

GlobeNewswire (Mon, 8:00AM)
Alimera Sciences And Trius Therapeutics: 2 Big Biotechs For 2013
Bob's Stocks • Mon, May 13 • 1 Comment
SmithOnStocks Opines On Recent Biotech News
Smith On Stocks • Mon, May 13 • 8 Comments
Trius Therapeutics Reports First Quarter 2013 Financial Results

GlobeNewswire (May 7, 2013)
Cramer's Mad Money - 10 Things To Watch In The Week Ahead (5/3/13)
SA Editor Miriam Metzinger • Sun, May 5 • 4 Comments
Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential
Life Sciences Report • Fri, May 3 • 3 Comments
Undue Pressure On Trius Creates An Entrance Point
PropThink • Thu, May 2 • 3 Comments
Trius Therapeutics Presents Clinical Data on Experimental Antibiotic Tedizolid at ECCMID Meeting

GlobeNewswire (Apr 29, 2013)
Trius Therapeutics to Present Experimental Antibiotic Study Results at ECCMID Meeting

GlobeNewswire (Apr 23, 2013)
GTx And Trius Therapeutics: 2 Top Biotech Buys For 2013
Bob's Stocks • Wed, Apr 17 • 4 Comments
Companies That Can Mend The Biotech Market: Stephen Brozak
Life Sciences Report • Fri, Apr 12 • 7 Comments
Trius: Clinical Trials Show Important Differentiation Of Tedizolid From Zyvox
Smith On Stocks • Tue, Apr 9 • 13 Comments
Trius Appoints Seth Fischer to Its Board of Directors

GlobeNewswire (Apr 3, 2013)
Trius to Present at Future Leaders Conference

GlobeNewswire (Apr 2, 2013)
Pfizer May Have To Rethink Xalkori Cost Structure
John Mylant • Fri, Mar 29 • 13 Comments
Trius Announces Positive Results From ESTABLISH 2 Study of Tedizolid in Severe Skin Infections

GlobeNewswire (Mar 25, 2013)
Trius Therapeutics Is A Strong Investment Short And Long Term
John Eastman • Thu, Mar 21 • 16 Comments

To learn more about Seeking Alpha Pro, click here.

Trius Patent Intrigues Investors, And Perhaps Cubist Pharmaceuticals
PropThink • Thu, May 16 • 3 Comments
Trius Therapeutics: New, Positive Dimension For Investment Outlook
Smith On Stocks • Mon, May 13 • 5 Comments
Undue Pressure On Trius Creates An Entrance Point
PropThink • Thu, May 2 • 3 Comments
GTx And Trius Therapeutics: 2 Top Biotech Buys For 2013
Bob's Stocks • Wed, Apr 17 • 4 Comments
Trius: Clinical Trials Show Important Differentiation Of Tedizolid From Zyvox
Smith On Stocks • Tue, Apr 9 • 13 Comments
Trius Therapeutics Is A Strong Investment Short And Long Term
John Eastman • Thu, Mar 21 • 16 Comments
Trius: Topline Data From Second Phase III Trial Of Tedizolid Is Imminent
Smith On Stocks • Mon, Mar 18 • 8 Comments
Trius: Phase III Data For Tedizolid Imminent
PropThink • Thu, Mar 14 • 3 Comments
Trius: Establishing A Compelling Case For Tedizolid
David Sobek • Tue, Mar 5 • 15 Comments
Trius Therapeutics: New MRSA Treatment Could Bring Billions In Revenues
Scott Matusow • Tue, Mar 5 • 8 Comments
Time To Dump Diluted Shares Of Trius - Or Double Down?
Rex Graham • Tue, Feb 12 • 5 Comments
Trius Therapeutics: Takeover Candidate In 2013
Bob's Stocks • Mon, Feb 4 • 11 Comments
Why The Trius Offering Is A Positive Move
John Eastman • Wed, Jan 23 • 4 Comments
Trius: Why Last Friday's Equity Offering Is Good For The Stock
Smith On Stocks • Mon, Jan 21 • 6 Comments
The Momentum Of Trius Therapeutics
Steven Barnes • Fri, Jan 18
Trius: In An About Face, Congress Is Helping Biotech Companies That Are Developing Antibiotics
Smith On Stocks • Mon, Jan 14 • 11 Comments
The Impact Of Off-Label Use Of Zyvox And Its Import For Trius And Tedizolid
David Sobek • Thu, Jan 10 • 4 Comments
Trius Quickens Pace Towards Commercialization With FDA Designation For Tedizolid Phosphate
John Eastman • Mon, Jan 7
End Of The Year Shopping Spree Should Have Trius On The List
Kyle Rankin • Fri, Dec 28, 2012 • 1 Comment
Resistance (To Resistance) Is Futile: The Growing Opportunity For Trius And Tedizolid
David Sobek • Thu, Dec 20, 2012 • 6 Comments

SmithOnStocks Opines On Stocks: May 19th Edition
Smith On Stocks • Sun, May 19 • 2 Comments
Alimera Sciences And Trius Therapeutics: 2 Big Biotechs For 2013
Bob's Stocks • Mon, May 13 • 1 Comment
SmithOnStocks Opines On Recent Biotech News
Smith On Stocks • Mon, May 13 • 8 Comments
Cramer's Mad Money - 10 Things To Watch In The Week Ahead (5/3/13)
SA Editor Miriam Metzinger • Sun, May 5 • 4 Comments
Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential
Life Sciences Report • Fri, May 3 • 3 Comments
Companies That Can Mend The Biotech Market: Stephen Brozak
Life Sciences Report • Fri, Apr 12 • 7 Comments
Pfizer May Have To Rethink Xalkori Cost Structure
John Mylant • Fri, Mar 29 • 13 Comments
Upcoming Catalysts For These BioPharmas Provide Potential Upside
Scott Matusow • Wed, Feb 20 • 20 Comments
Ram Selvaraju: Fall In Love With These Biotech Stocks
Life Sciences Report • Thu, Feb 14 • 1 Comment
Stephen Brozak: Changing The Way Money Is Made And Diseases Are Cured
Life Sciences Report • Fri, Jan 25 • 3 Comments
Meetings With Management: JPM Healthcare And The Biotech Showcase
PropThink • Fri, Jan 11 • 19 Comments
Biotechnology In 2012: The Best Performing Industry
Ryan's View • Tue, Dec 4, 2012
What George Carlin Taught Us About The Race For New Antibiotics
Austrolib • Mon, Oct 29, 2012 • 2 Comments
Who Is Paying Attention To MRSA?
Roy Smith • Tue, Oct 23, 2012 • 3 Comments
The Company You Keep Speaks Volumes: Novabay And Trius
John Eastman • Tue, Oct 9, 2012 • 2 Comments
Trius And OncoGenex Pharmaceuticals: On Their Game
Steven Barnes • Thu, Sep 13, 2012 • 1 Comment
5 Pharmaceutical Companies With Phase III Clinical Study Catalysts During The Next 4 - 12 Months
Markus Aarnio • Tue, Aug 21, 2012 • 8 Comments
IPO Preview: Durata Therapeutics
IPOdesktop • Wed, Jul 18, 2012
Micro Cap Biotech Stocks Being Accumulated By The World's Largest Money Managers
GuruFundPicks • Wed, Jul 11, 2012 • 9 Comments
GAIN Act Should Benefit Antibiotic Makers
Jason Napodano • Wed, Jun 27, 2012 • 3 Comments

There are no Transcripts on TSRX.

Trius Announces Notice of Allowance of U.S. Patent Application Related to Tedizolid Phosphate Combination With Daptomycin

GlobeNewswire (Mon, 8:00AM)
Trius Therapeutics Reports First Quarter 2013 Financial Results

GlobeNewswire (May 7, 2013)
Cramer's Home Work: A New Biopharma Idea

at CNBC.com (May 3, 2013)
Lightning Round: PulteGroup, Expedia & More

at CNBC.com (May 1, 2013)
Trius Therapeutics Presents Clinical Data on Experimental Antibiotic Tedizolid at ECCMID Meeting

GlobeNewswire (Apr 29, 2013)
Trius Therapeutics to Present Experimental Antibiotic Study Results at ECCMID Meeting

GlobeNewswire (Apr 23, 2013)
Trius Appoints Seth Fischer to Its Board of Directors

GlobeNewswire (Apr 3, 2013)
Trius to Present at Future Leaders Conference

GlobeNewswire (Apr 2, 2013)
Trius Announces Positive Results From ESTABLISH 2 Study of Tedizolid in Severe Skin Infections

GlobeNewswire (Mar 25, 2013)
Trius Therapeutics Reports 2012 Fourth Quarter and Full Year 2012 Financial Results

GlobeNewswire (Mar 12, 2013)
Trius Announces Publication of Tedizolid ESTABLISH 1 Trial in JAMA

GlobeNewswire (Feb 12, 2013)
Trius Therapeutics, Inc. Announces Exercise of Underwriters' Option to Purchase Additional Shares for Common Stock Offering

GlobeNewswire (Jan 23, 2013)
Trius Therapeutics, Inc. Prices Public Offering of Common Stock

GlobeNewswire (Jan 18, 2013)
Trius Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

GlobeNewswire (Jan 17, 2013)
Tedizolid Receives Qualified Infectious Disease Product (QIDP) Designation From FDA

GlobeNewswire (Jan 7, 2013)
Trius Therapeutics Completes Enrollment in Second Phase 3 Trial of Tedizolid for Skin and Skin Structure Infections

GlobeNewswire (Dec 10, 2012)
Trius Therapeutics Ranked Number 42 Fastest Growing Company in North America on Deloitte's 2012 Technology Fast 500(TM)

GlobeNewswire (Nov 14, 2012)
Trius to Present at November Investor Conferences

GlobeNewswire (Nov 12, 2012)
Trius Therapeutics to Host Analyst and Investor Update Call

GlobeNewswire (Nov 8, 2012)
Trius Therapeutics Reports 2012 Third Quarter Financial Results

GlobeNewswire (Nov 5, 2012)

TSRX vs. ETF Alternatives

Company Description

Currently, there's no company description for TSRX.

Sector: Healthcare

Industry: Medical Laboratories & Research

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, May 14, 3:34 PM Shares of Alimera Sciences (ALIM +22%) churn higher again today, racking up a +55% run over the past three days. The stock has been on the move since announcing in its 10-K that Iluvien had become commercially available in the UK, Germany, France, Spain, Portugal and Austria. Sentiment may also be getting a boost today on a Seeking Alpha article calling the stock an easy double at current levels, and, along with Trius Therapeutics (TSRX +7.7%), could be one of the biggest gainers in 2013. Comment! [Healthcare, On the Move, Global & FX]
Tuesday, May 14, 11:39 AM Shares of Trius Therapeutics (TSRX +5.6%) gain this morning after the company announced late yesterday that it's received a Notice of Allowance from the USPTO on an application related to its tedizolid phosphate patent portfolio. The new application protects a therapeutic combination of the experimental medicine with a currently available antibiotic daptomycin. Together, TSRX claims the medicines can prevent the development of certain strains of staph infection. Comment! [Healthcare, On the Move]
Tuesday, May 7, 8:05 PM Trius Therapeutics (TSRX): Q1 EPS of -$0.38 misses by $0.02. Revenue of $1.73M misses by $3.78M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Monday, March 25, 9:10 AM Premarket gainers: ZAZA +21%. ARWR +14%. APOL +9%. TSRX +5%. Losers: IDIX -10%. OTT -10%. UTHR -7%. PGTI -6%. Comment! [On the Move]
Wednesday, March 13, 11:52 AM Trius Therapeutics (TSRX +3.7%) moves up after reporting a Q4 loss that beat estimates. Revenue was also better, coming in at $5.2M, versus $5M the prior year. Net losses were higher, largely due to clinical and nonclinical development activities for tedizolid phosphate, our lead investigational drug in Phase 3 clinical development. 1 Comment [Healthcare, Earnings, On the Move]
Tuesday, March 12, 4:26 PM Trius Therapeutics (TSRX): Q4 EPS of -$0.36 beats by $0.11. Revenue of $5.2M beats by $0.6M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Friday, January 18, 12:45 PM Midday top 10 gainers: GFED +19%. DOM +12%. BTUI +11%. LIFE +11%. ONP +10%. ZA +10%. SGOC +9%. DQ +9%. MOV +9%. PRTS +9%.
Midday top 10 Losers: TELOZ -10%. HMNY -10%. TESS -9%. VOC -9%. COF -8%. CTC -8%. SINO -8%. TSRX -7%. BOSC -7%. FNSR -7%. Comment! [On the Move]
Friday, January 18, 10:46 AM Antibacterial-drug developer Trius Therapeutics (TSRX -8.22%) slips after pricing a 6.3M share secondary offering at $4.75 a share, a 9% discount to yesterday's close. The company made the announcement late yesterday without any details as to its size or scope. TSRX has a market cap of around $213M with a 39.4M share float. Comment! [On the Move]
Friday, January 18, 9:10 AM Premarket gainers: PATH +16%. LIFE +12%. NEWL +8%. RIMM +8%. MS +7%. SNE +7%. GERN +5%.
Losers: FNSR -10%. TSRX -9%. WIT -8%. COF -7%. INTC -6%.
2 Comments [On the Move]
Thursday, January 17, 5:40 PM After-hours top gainers, as of 5:15 p.m.: AM +9%. ARAY +4%. SOXS +3%. EGLE +3%. ONXX +2%.
After-hours top losers: COF -8%. TSRX -6%. PATH -5%. INTC -4%. MAKO -3%. Comment! [On the Move]
Thursday, January 17, 5:04 PM Trius Therapeutics (TSRX) announces a secondary offering, no details as to the actual size or terms of the offering have been disclosed. Citigroup and Leerink Swann are acting as joint book-running managers and Baird is acting as a co-lead manager. Shares -5.5% AH. Comment! [Healthcare, On the Move]
Monday, January 7, 3:02 PM Trius Therapeutics (TSRX +0.7%) says the FDA has designated it's Phase 3 antibiotic candidate, tedizolid phosphate, as a Qualified Infectious Disease Product for acute bacterial skin and skin structure infections, as well as for hospital-acquired/ventilator-associated bacterial pneumonia. The designation enables the company to benefit from certain incentives for the development of new antibiotics, including priority review and fast-track status. Comment! [Healthcare, On the Move]
Wednesday, June 27, 2012, 11:48 AM Trius Therapeutics (TSRX +1.2%) comments on Congress's approval of the Prescription Drug Users Fee Act, saying it contains key incentives for antibiotic drug developers. The Act, which is expected to be signed into law by President Obama next week, will provide drug developers with new regulatory options to aid in the development of new treatments for infections caused by drug resistant bacteria. Comment! [Healthcare]
Thursday, January 26, 2012, 10:49 AM Trius Therapeutics (TSRX -7.6%) says the SEC is requesting more information about its Q3 revenue. The request is related to a collaboration and license agreement it has with Bayer to develop and market its first antibiotic drug candidate, torezolid phosphate. The company swung to a profit in that quarter because of payments from its agreement with Bayer. Comment! [Healthcare, On the Move]
Wednesday, January 25, 2012, 7:56 PM Trius Therapeutics (TSRX) trades down after hours following its announcement of a secondary offering with undisclosed terms. Citigroup and Piper Jaffray are acting as joint book-runners. Shares -7.6% AH. Comment! [Healthcare, On the Move]
Friday, December 23, 2011, 9:01 AM Baird initiates coverage on Trius Therapeutics (TSRX) with an Outperform rating and $13 price target. Analysts with the firm call the biopharmaceutical a "very high quality company and recently de-risked story" on the strength of its pipeline and position in the MRSA hospital infection market. Shares +10.2% premarket. Comment! [Healthcare, On the Move]

Ryan Mallory
Fuinhaz Setups for May 13 2013 | $TSRX $UNIS $WCRX | SharePlanner http://bit.ly/17Xh5h3
Mon, 9:31 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

tomfalbo
LONG $TSRX $ATHX - bought big on every dip - take profits accordingly - large core holdings - 2013/14 big years
Apr 2, 11:09 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Ryan Mallory
Fuinhaz Setups for March 25 2013 | $ACAD $APOL $ARMH $ARNA $DELL $DRYS $TSRX $VOD $ZNGA | SharePlanner http://bit.ly/11CM96b
Mar 25, 9:18 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

tomfalbo
guna b a gud ME for $APPA.OB, $INO, $TSRX
Mar 19, 8:51 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

yalqassar
$TSRX
Mar 6, 8:03 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Scott Matusow
Trade call success on $TSRX Just printed a $6 needed this one after $CYCC not so well -- yet
Mar 5, 3:28 PM
Reply (8)

• !Report Abuse
View all 8 replies
u681694: Do you still think CYCC has long term potential as per your article ?
Mar 6, 3:06 PM
• !Report Abuse
Scott Matusow: yes i do. but speculation wise. what if what goes down? what if a crazy man pisses on my lawn tomorrow?
Mar 6, 6:49 PM
• !Report Abuse
Add a reply...

140 characters

Cabeza Howe
Guess $TSRX's latest share issuance at $4.46 was to give Terrapin a deal. Co. might have treated Terrapin as a partner. I could be wrong.
12/14/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Cabeza Howe
$TSRX is special: tanked on good news (trial recruit) then spiked on bad news (equity draw down). But I'm taking bulk of it off table now.
12/14/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Cabeza Howe
$TSRX is looking attractive at this price level.
12/12/12
Reply (1)

• !Report Abuse
View all 1 replies
joe kelly: Figures. Finally had available cash to get tsrx and it's 30cents higher today. Dang.
12/13/12
• !Report Abuse
Add a reply...

140 characters

Joshua Hayes
Medical drug/biotech stocks under accumulation recently $ONXX $INHX $CBM $RPTP $ARIA $AKRX $PCYC $WCG $SPPI $TSRX $HITK $STAA
11/29/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Scott Matusow
Trade call success on $TSRX Just printed a $6 needed this one after $CYCC not so well -- yet
Mar 5, 3:28 PM
Reply (8)

• !Report Abuse
View all 8 replies
u681694: Do you still think CYCC has long term potential as per your article ?
Mar 6, 3:06 PM
• !Report Abuse
Scott Matusow: yes i do. but speculation wise. what if what goes down? what if a crazy man pisses on my lawn tomorrow?
Mar 6, 6:49 PM
• !Report Abuse
Add a reply...

140 characters

Cabeza Howe
$TSRX is looking attractive at this price level.
12/12/12
Reply (1)

• !Report Abuse
View all 1 replies
joe kelly: Figures. Finally had available cash to get tsrx and it's 30cents higher today. Dang.
12/13/12
• !Report Abuse
Add a reply...

140 characters

TSRX Trius Therapeutics, Inc.

TSRX

Trius Therapeutics, Inc.